Research advances on circulating long noncoding RNAs as biomarkers of cardiovascular diseases

Cao, Mingyi; Luo, Huishan; Li, Danning; Wang, Shengjie; Xuan, Lina; Sun, Lihua

doi:10.1016/j.ijcard.2022.01.070

Cited by 35 publications

(13 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in the GAS5 gene expression have not been previously associated with metformin treatment. Nevertheless, there are multiple studies associating the expression of this lncRNA with diseases that are currently treated with metformin, including diabetes [ 35 ], cardiovascular diseases [ 36 ], and cancer [ 37 ]. GAS5 has over 70 annotated isoforms and is one of the lncRNAs with the highest number of transcripts.…”

Section: Resultsmentioning

confidence: 99%

Metformin Treatment Modulates Long Non-Coding RNA Isoforms Expression in Human Cells

Conceição

Dias

Queiroz

et al. 2022

ncRNA

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) undergo splicing and have multiple transcribed isoforms. Nevertheless, for lncRNAs, as well as for mRNA, measurements of expression are routinely performed only at the gene level. Metformin is the first-line oral therapy for type 2 diabetes mellitus and other metabolic diseases. However, its mechanism of action remains not thoroughly explained. Transcriptomic analyses using metformin in different cell types reveal that only protein-coding genes are considered. We aimed to characterize lncRNA isoforms that were differentially affected by metformin treatment on multiple human cell types (three cancer, two non-cancer) and to provide insights into the lncRNA regulation by this drug. We selected six series to perform a differential expression (DE) isoform analysis. We also inferred the biological roles for lncRNA DE isoforms using in silico tools. We found the same isoform of an lncRNA (AC016831.6-205) highly expressed in all six metformin series, which has a second exon putatively coding for a peptide with relevance to the drug action. Moreover, the other two lncRNA isoforms (ZBED5-AS1-207 and AC125807.2-201) may also behave as cis-regulatory elements to the expression of transcripts in their vicinity. Our results strongly reinforce the importance of considering DE isoforms of lncRNA for understanding metformin mechanisms at the molecular level.

show abstract

Section: Resultsmentioning

confidence: 99%

Metformin Treatment Modulates Long Non-Coding RNA Isoforms Expression in Human Cells

Conceição

Dias

Queiroz

et al. 2022

ncRNA

View full text Add to dashboard Cite

show abstract

“…HOTAIR has been suggested to play roles in oncogenesis [ 35 ], heart disease [ 36 ], and nervous system functions [ 37 ]. HOTAIR has been proposed as a possible biomarker for cardiovascular diseases [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Association of Polymorphisms in the Long Non-Coding RNA HOTAIR with Recurrent Pregnancy Loss in a Korean Population

Park

Kim

Lee

et al. 2022

Genes

View full text Add to dashboard Cite

Recurrent pregnancy loss (RPL) affects 1% to 5% of women, with devastating effects on both reproductive health and psychological well-being. Homeobox (HOX) transcript antisense RNA (HOTAIR) is a long non-coding RNA (lncRNA) produced by HOXC; it plays a major role in invasion and development of ovarian and other cancers. The aim of the present study was to analyze effects of HOTAIR polymorphisms (rs4759314 A>G, rs920778 T>C, rs1899663 G>T, and rs7958904 G>C) on RPL in Korean women. A total of 403 women with RPL and 383 healthy women were selected for this study. Genotyping analysis was performed with the polymerase chain reaction, restriction fragment length polymorphism, and the TaqMan genotyping assay. Clinical characteristics were compared using Student’s unpaired t-test and the chi-square test for categorical variables. Logistic regression was performed to evaluate associations between single nucleotide polymorphisms and RPL incidence. In all assays, p < 0.05 was considered significant. HOTAIR polymorphisms rs4759314A>G and rs920778T>C were highly associated with increased risk of RPL, specifically the haplotypes rs4759314A>G/rs1899663G>T (G-T) and rs4759314A>G/rs920778 T>C (G-C). These associations were maintained in haplotypes that contained three polymorphisms (rs4759314 A>G, rs920778 T>C, and rs1899663 G>T) A-C-G, G-T-G, and G-T-T, further indicating that the HOTAIR rs4759314 and rs920778 polymorphisms play significant roles in idiopathic RPL in Korean women.

show abstract

“…Besides their role in CVD, lncRNAs may also act as causal biomarkers and may help distinguish among different conditions, thus helping in differential diagnosis. The combination of classic biomarkers with lncRNA signatures is indeed emerging as a novel and promising tool to stratify the risk of developing CVD and HF ( 161 ).…”

Section: Promising Novel Epi-drugs With Potential Use In Heart Failurementioning

confidence: 99%

Epi-Drugs in Heart Failure

Gorica

Mohammed

Ambrosini

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Unveiling the secrets of genome’s flexibility does not only foster new research in the field, but also gives rise to the exploration and development of novel epigenetic-based therapies as an approach to alleviate disease phenotypes. A better understanding of chromatin biology (DNA/histone complexes) and non-coding RNAs (ncRNAs) has enabled the development of epigenetic drugs able to modulate transcriptional programs implicated in cardiovascular diseases. This particularly applies to heart failure, where epigenetic networks have shown to underpin several pathological features, such as left ventricular hypertrophy, fibrosis, cardiomyocyte apoptosis and microvascular dysfunction. Targeting epigenetic signals might represent a promising approach, especially in patients with heart failure with preserved ejection fraction (HFpEF), where prognosis remains poor and breakthrough therapies have yet to be approved. In this setting, epigenetics can be employed for the development of customized therapeutic approaches thus paving the way for personalized medicine. Even though the beneficial effects of epi-drugs are gaining attention, the number of epigenetic compounds used in the clinical practice remains low suggesting that more selective epi-drugs are needed. From DNA-methylation changes to non-coding RNAs, we can establish brand-new regulations for drug targets with the aim of restoring healthy epigenomes and transcriptional programs in the failing heart. In the present review, we bring the timeline of epi-drug discovery and development, thus highlighting the emerging role of epigenetic therapies in heart failure.

show abstract

Research advances on circulating long noncoding RNAs as biomarkers of cardiovascular diseases

Cited by 35 publications

References 64 publications

Metformin Treatment Modulates Long Non-Coding RNA Isoforms Expression in Human Cells

Metformin Treatment Modulates Long Non-Coding RNA Isoforms Expression in Human Cells

Association of Polymorphisms in the Long Non-Coding RNA HOTAIR with Recurrent Pregnancy Loss in a Korean Population

Epi-Drugs in Heart Failure

Contact Info

Product

Resources

About